Oncology News | pharmaphorum

News

AZ/Merck & Co's Lynparza delays spread of pancreatic cancer

AstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after a trial showed it slowed progression of the disease.

News

Two new cancer Priority Reviews for Roche

Roche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung cancer medicine entrectinib and lymphoma treatment polat

News

Keytruda combo set to become "standard of care" in kidney ca...

Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a pr

News

Bayer takes control of Loxo duo as Lilly closes takeover

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an

News

Trial could unlock new prostate cancer sales for Pfizer/Aste...

Pfizer and Astellas’ Xtandi has shown it is effective in men with prostate cancer that has spread but has not yet become hormone resistant, stepping up pressure on rival therapy Zytiga from Johnson

News

NICE backs Takeda's Alunbrig in second-line lung cancer

NICE has published final draft guidance recommending regular NHS funding in England for Takeda’s Alunbrig (brigatinib), for ALK-positive advanced non-small cell lung cancer, in patients alr

AZ/Merck & Co's Lynparza delays spread of pancreatic cancer

Two new cancer Priority Reviews for Roche

Keytruda combo set to become "standard of care" in kidney ca...

Bayer takes control of Loxo duo as Lilly closes takeover

Trial could unlock new prostate cancer sales for Pfizer/Aste...

NICE backs Takeda's Alunbrig in second-line lung cancer

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks